Conflict of Interest Disclosures: Dr Nierenberg reported personal fees from Abbott, Alkermes, Altimate, Bristol Myers Squibb, Clexio, Delix, Eisai, Flow Neuroscience, Ginger/Headspace Health, Janssen, Johnson & Johnson, Merck, Milken Center for Strategic Philosophy, Myriad, Neurocrine, Neuronetics, NeuroRx, Novartis, Otsuka, Protagenics, Sage, Seaport Therapeutics, Sunovion, Unravel Bioscience, and 4M Therapeutics, honoraria from Belvior, Eisai, Psychiatric Annals /SLACK Publications, and Depression and Anxiety /Wiley, royalties from Guilford Publications and UpToDate/Wolters Kluwer Health, and participation in an adjudication committee for Novartis outside the submitted work; in addition, Dr Nierenberg had a patent for ELi12 issued. Dr Zarate reported being listed as a coinventor on patents for the use of ketamine and its metabolites for depression and suicide, the use of ketamine and its metabolites in major depression and suicidal ideation, and the use of ( 2R,6R )-hydroxynorketamine, ( S )-dehydronorketamine, and other stereoisomeric dehydroxylated and hydroxylated metabolites of ( R,S )-ketamine in the treatment of depression and neuropathic pain and as a coinventor on a patent application for the use of ( 2R,6R )-hydroxynorketamine and ( 2S,6S )-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and posttraumatic stress disorder; he has assigned his patent rights to the US government but will share a percentage of any royalties that may be received by the government. Dr Correll reported royalties from UpToDate, serving as a consultant and/or advisor to or receiving honoraria from AbbVie, Alkermes, Allergan, Angelini, Aristo, Boehringer Ingelheim, Bristol Myers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Eli Lilly, Gedeon Richter, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/Johnson & Johnson, Karuna, LB Pharma, Lundbeck, Maplight, MedInCell, MedLink, Merck, Mindpax, Mitsubishi Tanabe Pharma, Mylan, Neumora Therapeutics, Neurelis, Neurocrine, Newron, Noven, Novo Nordisk, Otsuka, PPD Biotech, Recordati, Relmada, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris, and Xenon Pharmaceuticals, providing expert testimony for Janssen, Lundbeck, and Otsuka, serving on a data safety monitoring board for Compass Pathways, IntraCellular Therapies, Relmada, Reviva, and Rovi, receiving grants from Boehringer Ingelheim, Janssen, and Takeda, and having stock options in Cardio Diagnostics, Kuleon Biosciences, LB Pharma, Medlink, Mindpax, Quantic, and Terran outside the submitted work. Dr McIntyre reported grants from the Canadian Institutes of Health Research, Global Alliance for Chronic Diseases, National Natural Science Foundation of China, and Milken Institute and personal fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe Pharma, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Neurawell, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, AbbVie, Bristol Myers Squibb, and Atai Life Sciences outside the submitted work. Dr Krystal reported serving on the scientific advisory board of Freedom Biosciences, personal fees from AbbVie, Alkermes, Alpha Wave Global, ARIA, Beckley Psytech, Biogen, Boehringer Ingelheim, Clearmind, Cybin, Firebird Pharmaceuticals, Freedom Biosciences, Gemini Sciences, GH Research, Janssen Pharmaceuticals, Jazz Pharmaceuticals, Leal Therapeutics, Neumora Therapeutics, Neurocrine, Newlos, Novartis, Otsuka America Pharmaceuticals, Phrenix Therapeutics, Psylo, Response Pharmaceuticals, Reunion Neuroscience, Society of Biological Psychiatry, Takeda Pharmaceuticals, and WebMD/Medscape, stock from Freedom Biosciences and Spring Health, options from Rest Pharmaceuticals, Clearmind, Draig Therapeutics, Epivarioo, Eumentis Therapeutics, Psylo PTD, Temero Bio, Terran Biosciences, and Tetricus, stock and options from Biohaven Pharmaceuticals, equity in Biohaven Pharmaceuticals, Biohaven Pharmaceuticals Medical Sciences, Clearmind Medicine, EpiVario, Neumora Therapeutics, Tempero Bio, Terran Biosciences, Tetricus, and Spring Care, and consulting for AE Research Foundation, Aptinyx, Biohaven Pharmaceuticals, Biogen, Bionomics, Ltd (Australia), BioXcel Therapeutics, Boehringer Ingelheim International, Cerevel Therapeutics, Clearmind Medicine, Cybin IRL, Delix Therapeutics, Eisai, Enveric Biosciences, Epiodyne, EpiVario, Evidera, Freedom Biosciences, Janssen Research and Development, Jazz Pharmaceuticals, Leal Therapeutics, Neumora Therapeutics, Neurocrine Biosciences, Novartis Pharmaceuticals, Otsuka America Pharmaceutical, Perception Neuroscience, Praxis Precision Medicines, PsychoGenics, Spring Care, Sunovion Pharmaceuticals, Takeda Industries, Tempero Bio, Terran Biosciences, and Tetricus outside the submitted work; in addition, Dr Krystal had a patent for antidepressant and antisuicide effects of ketamine with royalties paid from Johnson & Johnson, a patent for extending ketamine efficacy with royalties paid from Freedom Biosciences, a patent for efficacy of riluzole with royalties paid from Biohaven Pharmaceuticals, a patent for nonhallucinatory psychedelic licensed to Biohaven Pharmaceuticals, a patent for nonaddictive MDMA (3,4-methylenedioxymethamphetamine) licensed to Freedom Biosciences, and a patent for nonaddictive ketamine licensed to Freedom Biosciences. Dr Rhee reported serving as a review committee member for the Patient-Centered Outcomes Research Institute (PCORI) and Substance Abuse and Mental Health Services Administration (SAMHSA), receiving honoraria from PCORI and SAMHSA, serving as a stakeholder or consultant for PCORI, receiving consulting fees from PCORI, and serving as an advisory committee member for the International Alliance of Mental Health Research Funders. No other disclosures were reported.
PubMed
Psychedelic Science